Encouraging Results from Phase 2 Trial Presented at Neurology Conference
Last month, Zynerba Pharmaceuticals, Inc. presented a poster to the Joint 16th International Child Neurology Congress & 49th Annual Child Neurology Society Meeting which described data from their Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial. The infographic demonstrated that their transdermal product, Zygel, can improve behavioral symptoms in individuals with autism. Zynerba’s Phase 2 BRIGHT trial included children and adolescents ages 3 to <18 years old who are on the moderate to severe end of the spectrum. Core symptoms of autism involve atypical behavior, communication challenges, peer interaction problems, repetitive behavior, and lack of social reciprocity. Each one of these areas showed improvement in the Phase 2 Bright trial as reported by caregivers. Zygel was shown to be well tolerated with no serious or severe adverse reactions reported with this trial.
